KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$2.4 billion.

  • Pfizer's Cash from Investing Activities fell 15684.21% to -$2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 billion, marking a year-over-year increase of 243161.95%. This contributed to the annual value of $2.7 billion for FY2024, which is 10821.61% up from last year.
  • Pfizer's Cash from Investing Activities amounted to -$2.4 billion in Q3 2025, which was down 15684.21% from $4.0 billion recorded in Q2 2025.
  • Pfizer's Cash from Investing Activities' 5-year high stood at $4.6 billion during Q2 2024, with a 5-year trough of -$25.5 billion in Q3 2023.
  • In the last 5 years, Pfizer's Cash from Investing Activities had a median value of -$590.0 million in 2021 and averaged -$4.3 billion.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 236056.34% in 2021, then skyrocketed by 48465.61% in 2023.
  • Pfizer's Cash from Investing Activities (Quarter) stood at -$20.0 billion in 2021, then soared by 43.02% to -$11.4 billion in 2022, then grew by 3.31% to -$11.0 billion in 2023, then skyrocketed by 138.88% to $4.3 billion in 2024, then tumbled by 156.84% to -$2.4 billion in 2025.
  • Its Cash from Investing Activities stands at -$2.4 billion for Q3 2025, versus $4.0 billion for Q2 2025 and $3.3 billion for Q1 2025.